Adial pharmaceuticals achieves 50% enrollment in onward™ phase 3 trial

Charlottesville, va., feb. 25, 2021 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it has reached 50% enrollment in the company's landmark onward™ pivotal phase 3 clinical trial. onward is investigating the efficacy and safety of adial's lead drug candidate, ad04, as a therapeutic agent for the treatment of alcohol use disorder (aud) in persons with certain target genotypes related to the serotonin transporter and receptor genes.
ADIL Ratings Summary
ADIL Quant Ranking